All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bcl-2 inhibitor APG-2575 receives FDA orphan drug designation for the treatment of AML
By Claire Baker
Bookmark this article
On January 4, 2021, APG-2575 was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with acute myeloid leukemia.1
APG-2575, a novel Bcl-2 inhibitor, can be administered orally and is being evaluated in a number of hematological malignances through international Phase Ib/II trials. The selective inhibition of Bcl-2 is hypothesized to reinstate functional apoptosis in malignant cells.2 APG-2575 has also received orphan drug designation for the following indications:
- Waldenström’s macroglobulinemia
- Chronic lymphocytic leukemia
- Multiple myeloma
- PRNewswire. Ascentage Pharma announces its 9th orphan drug designation from the US FDA in 2020, setting a record for Chinese biopharmaceutical companies. https://www.prnewswire.com/news-releases/ascentage-pharma-announces-its-9th-orphan-drug-designation-from-the-us-fda-in-2020-setting-a-record-for-chinese-biopharmaceutical-companies-301200596.html. Published Jan 4, 2021. Accessed Jan 7, 2021.
- PRNewswire. Ascentage Pharma's Bcl-2 Inhibitor APG-2575 granted orphan drug designation by the FDA for the treatment of chronic lymphocytic leukemia. https://www.prnewswire.com/news-releases/ascentage-pharmas-bcl-2-inhibitor-apg-2575-granted-orphan-drug-designation-by-the-fda-for-the-treatment-of-chronic-lymphocytic-leukemia-301124971.html. Published Sep 7, 2020. Accessed Jan 7, 2021.
More about...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox